FDA OTC drugs-of-abuse testing interim policy allows kits on market without preclearance.
This article was originally published in The Tan Sheet
Executive Summary
FDA OTC DRUG TESTING INTERIM POLICY ALLOWS HOME DRUG TESTS for drugs of abuse to go on the market without premarket review. The one-page interim agency policy, issued Oct. 3, spells out FDA's plan to soften its regulatory stance on home-use drug tests while it develops a final agency policy defining what, if any, premarket requirements should be imposed on the tests. Prior to the interim policy, OTC drugs-of-abuse tests were deemed Class III devices, subject to premarket approval application requirements.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning